Published Data in Metastatic Breast Cancer
SIR-Spheres® Y-90 resin microspheres have shown efficacy in the treatment of chemotherapy-refractory metastatic breast cancer (mBC) and in the treatment of liver progression during a treatment hiatus.
Overall, 86% of patients with chemotherapy-refractory liver metastases from breast cancer or with liver progression during a treatment hiatus after first- or second-line chemotherapy were alive 14 months after receiving SIR-Spheres Y-90 resin microspheres.1
Several other studies have reported on the efficacy of SIR-Spheres Y-90 resin microspheres in chemorefractory mBC.2-4 OS has ranged from 35 weeks to 13.6 months in these studies, which compares well with historical controls.
The use of SIR-Spheres Y-90 resin microspheres in chemorefractory mBC is further supported by a high proportion of patients with partial response (26–47%) or stable disease (39–63%).1-3
Reported complications across studies have generally been minor, with most adverse events being grade 1 or 2 that resolved without intervention.4 Overall, SIR-Spheres Y-90 resin microspheres are an effective and well-tolerated treatment option for unresectable liver metastases from breast cancer, which are often chemotherapy-refractory, or for the treatment of liver progression during a treatment hiatus.
1 Coldwell, DM et al. Int J Radiat Oncol Biol Phys 2007; 69: 800-804.
2 Haug AR et al. J Nucl Med 2012; 53: 371-377.
3 Saxena A et al. Ann Surg Oncol 2014; 21: 1296-1303.
4 Fendler WP et al. J Nucl Med 2016; 57: 517-523.
Ongoing mBC Studies
Ongoing studies of SIR-Spheres® Y-90 resin microspheres in the treatment of mBC:
A two arm safety study of SIR-Spheres microspheres plus mitomycin C in patients with refractory breast cancer.
|Breast cancer||Investigator-Initiated Research Study||SIR Spheres Y-90 resin microspheres > mitomycin C||15||Belgium|